Fresh off one deal, Allergan CEO Saunders sets his sights on more

New York

ALLERGAN plc CEO Brent Saunders is ready to put the US$36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.

The readiness for a new transaction just after the Teva deal was announced on Monday represents what Mr Saunders calls a strategy to remain nimble and open to opportunity as the healthcare sector remakes itself.